JP5780693B2 - 免疫原性組成物 - Google Patents

免疫原性組成物 Download PDF

Info

Publication number
JP5780693B2
JP5780693B2 JP2008546433A JP2008546433A JP5780693B2 JP 5780693 B2 JP5780693 B2 JP 5780693B2 JP 2008546433 A JP2008546433 A JP 2008546433A JP 2008546433 A JP2008546433 A JP 2008546433A JP 5780693 B2 JP5780693 B2 JP 5780693B2
Authority
JP
Japan
Prior art keywords
protein
seq
polypeptide
sbi
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008546433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009520758A (ja
JP2009520758A5 (https=
Inventor
カスタード，シンディ
ネイト，セシル，アンヌ
プールマン，ジャン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2009520758A publication Critical patent/JP2009520758A/ja
Publication of JP2009520758A5 publication Critical patent/JP2009520758A5/ja
Application granted granted Critical
Publication of JP5780693B2 publication Critical patent/JP5780693B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008546433A 2005-12-21 2006-12-19 免疫原性組成物 Expired - Fee Related JP5780693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526038A GB0526038D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526038.5 2005-12-21
PCT/EP2006/069944 WO2007071692A2 (en) 2005-12-21 2006-12-19 Immunogenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013117514A Division JP2013215197A (ja) 2005-12-21 2013-06-04 免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2009520758A JP2009520758A (ja) 2009-05-28
JP2009520758A5 JP2009520758A5 (https=) 2010-02-12
JP5780693B2 true JP5780693B2 (ja) 2015-09-16

Family

ID=35840898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008546433A Expired - Fee Related JP5780693B2 (ja) 2005-12-21 2006-12-19 免疫原性組成物
JP2013117514A Pending JP2013215197A (ja) 2005-12-21 2013-06-04 免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013117514A Pending JP2013215197A (ja) 2005-12-21 2013-06-04 免疫原性組成物

Country Status (7)

Country Link
US (2) US20080311146A1 (https=)
EP (1) EP1962890B1 (https=)
JP (2) JP5780693B2 (https=)
CA (1) CA2634898A1 (https=)
ES (1) ES2558703T3 (https=)
GB (1) GB0526038D0 (https=)
WO (1) WO2007071692A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021215462A1 (ja) * 2020-04-23 2021-10-28 ブライトパス・バイオ株式会社 改良ペプチドワクチン

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
EP2099932A4 (en) 2006-12-06 2009-11-18 Repligen Corp NUCLEIC ACIDS ENCODING THE RECOMBINANT PROTEIN A
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
HUE034251T2 (en) 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
US9974848B2 (en) 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
US10195262B2 (en) * 2013-12-04 2019-02-05 Glaxosmithkline Biologicals S.A. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
CN103694322B (zh) * 2013-12-09 2016-08-17 成都欧林生物科技股份有限公司 金黄色葡萄球菌SpA5突变体及其制备方法和应用
CN106103469B (zh) 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
GB201619965D0 (en) * 2016-11-25 2017-01-11 Univ Of Bath The Immunogenic compositions comprising sbi protein and uses thereof
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2024129976A2 (en) * 2022-12-14 2024-06-20 Scribe Therapeutics Inc. Particle delivery systems

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571514A (en) * 1987-06-01 1996-11-05 Alfa Laval Ab Fibronectin binding protein as well as its preparation
SE9704141D0 (sv) 1997-11-12 1997-11-12 Sbl Vaccin Ab New protein and nucleotide sequence, encoding said protein
EP1121149A4 (en) 1998-08-31 2002-03-20 Inhibitex Inc IMMUNOTHERAPEUTICS AGAINST STAPHYLOCOCCUS USING DONOR SELECTION AND DONOR STIMULATION
ES2322409T3 (es) 1998-08-31 2009-06-19 Inhibitex, Inc. Vacunas multicomponentes contra staphylococcus aureus.
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US7098383B2 (en) * 2000-12-19 2006-08-29 Sembiosys Genetics Inc. Methods for the production of multimeric immunoglobulins, and related compositions
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CA2517439C (en) * 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
KR20060065643A (ko) * 2003-07-24 2006-06-14 머크 앤드 캄파니 인코포레이티드 스타필로코쿠스 아우레우스에 대한 방어 면역 반응을유도하는 폴리펩타이드
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021215462A1 (ja) * 2020-04-23 2021-10-28 ブライトパス・バイオ株式会社 改良ペプチドワクチン

Also Published As

Publication number Publication date
WO2007071692A3 (en) 2007-09-13
ES2558703T3 (es) 2016-02-08
WO2007071692A2 (en) 2007-06-28
JP2009520758A (ja) 2009-05-28
US20150125481A1 (en) 2015-05-07
CA2634898A1 (en) 2007-06-28
GB0526038D0 (en) 2006-02-01
US20080311146A1 (en) 2008-12-18
EP1962890B1 (en) 2015-11-11
EP1962890A2 (en) 2008-09-03
JP2013215197A (ja) 2013-10-24

Similar Documents

Publication Publication Date Title
JP2013215197A (ja) 免疫原性組成物
JP6594385B2 (ja) 免疫原性組成物
AU2018201768B2 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
EP1185297B1 (en) Streptococcus pneumoniae proteins and vaccines
JP2013501027A (ja) 抗原性黄色ブドウ球菌タンパク質を含む免疫原性組成物
KR102393038B1 (ko) OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도
RU2757426C2 (ru) Иммунногенный слитый белок
JP2010057501A (ja) 肺炎球菌感染を治療または予防するための組成物および方法
JP5922573B2 (ja) ブドウ球菌クランピング因子ａの変異体を含む免疫原性組成物
US6887480B1 (en) Streptococcus pneumoniae proteins and vaccines
JP6401148B2 (ja) 抗原および抗原の組み合わせ
US20110171224A1 (en) PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
HK1250933A1 (en) Immunogenic fusion protein
HK1175704A (en) Immunogenic composition for use in vaccination against staphylococcei

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130604

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130613

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150714

R150 Certificate of patent or registration of utility model

Ref document number: 5780693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees